^
    2ms
    Identification and non-clinical characterization of SAR444200, a novel anti-GPC3 NANOBODY® T-cell engager, for the treatment of GPC3+ solid tumors. (PubMed, Mol Cancer Ther)
    The highly potent and efficacious activity of SAR444200 in diverse models of GPC3+ tumors and the extremely wide tolerated dose range merits further development of this compound. Furthermore, NANOBODY®-based TCEs developed using an anti-TCRαβ moiety may have specific advantages for the development of TCEs.
    Journal • IO biomarker
    |
    GPC3 (Glypican 3) • CD3E (CD3 Epsilon Subunit Of T-Cell Receptor Complex)
    |
    SAR444200
    2ms
    Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma. (PubMed, Semin Nucl Med)
    First-in-human studies, including 124I-codrituzumab and 68Ga-RAYZ-8009, confirmed tumor-specific accumulation but remained limited in scale...The available evidence suggests a preferential pathway, involving the selection of a limited set of lead vectors, their pairing with suitable radionuclides, validation in orthotopic/PDX models using standardized endpoints, and the integration of comprehensive dosimetric and toxicologic studies before proceeding to broader human trials. GPC3-directed theranostics thus offers a compelling, disease-specific route to precision management of HCC, provided translational rigor addresses the outlined safety and quantitative imaging gaps.
    Review • Journal
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)
    4ms
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P2, N=20, Recruiting, Eureka Therapeutics Inc. | N=30 --> 20
    Enrollment change
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    5ms
    Therapeutic Glypican-3 CRISPR Genome-Editing Using UltraLarge Porous Silica Nano-Depot for the Treatment of Hepatocellular Carcinoma. (PubMed, Small Sci)
    Furthermore, the GPC3 CRISPR-Cas9@UPSND treatment exhibits superior anti-proliferative efficacy in tumor-growth prevention compared to Codrituzumab, as evidenced by the analysis of Ki67 and GPC3 expression, along with serum GPC3 levels. These findings underscore the translational potential of the non-viral UPSND nanoplatform-based CRISPR GPC3 genome editing, offering a promising targeted therapeutic strategy for HCC treatment.
    Journal
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)
    6ms
    Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor. (PubMed, Int J Nanomedicine)
    Meanwhile, hGC33-OMVs suppressed HepG2 cell proliferation, induced G1-phase arrest, and reduced Wnt3a, β-catenin, Cyclin D1, and C-myc expression. Engineered E. coli hGC33-OMVs effectively target HCC via the hGC33-GPC3 interaction, inhibit tumor growth by suppressing Wnt signaling, and demonstrate potential for use as a versatile platform for antibody delivery.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCND1 (Cyclin D1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • GPC3 (Glypican 3) • PCNA (Proliferating cell nuclear antigen)
    |
    codrituzumab (RG7686)
    6ms
    Hepatocellular Carcinoma and Antibody Drug Conjugates: A Systematic Review. (PubMed, Cureus)
    Recent clinical trials have demonstrated that ADCs targeting GPC3, such as GC33 and 32A9, show promising results in reducing tumor growth and improving patient outcomes in advanced HCC...The exclusion criteria included languages other than English and publications before 2019. A total of 26 articles were identified, and 12 articles were selected after quality assessment.
    Review • Journal
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)
    7ms
    A First-in-Human, Open-label, Phase 1/2 Study of BOS-342 in Patients with Hepatocellular Carcinoma (HCC) and other Glypican 3 (GPC3)-expressing Tumors (ACTRN12623000798662)
    P1/2, N=81, Terminated, Boston Pharmaceuticals, Inc. | Recruiting --> Terminated
    Trial termination
    |
    GPC3 (Glypican 3)
    |
    BOS-342 • methylprednisolone sodium succinate
    7ms
    A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=248, Recruiting, Keymed Biosciences Co.Ltd | N=92 --> 248 | Trial completion date: Mar 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    CM350
    8ms
    RHEA-1: First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours (clinicaltrials.gov)
    P1/2, N=304, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    8ms
    ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
    P2, N=30, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    cyclophosphamide • Stivarga (regorafenib) • ECT204
    9ms
    A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer (clinicaltrials.gov)
    P1, N=148, Recruiting, Bayer | Not yet recruiting --> Recruiting
    Enrollment open
    9ms
    A Study of Codrituzumab in Children and Young Adults with Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment (clinicaltrials.gov)
    P1, N=50, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2025 --> Jun 2026 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    codrituzumab (RG7686)